Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexander KP, Newby LK, Ay H, Gibler WB: Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation. 2010, 121 (14): 1664-1682. 10.1161/CIR.0b013e3181d4b43e.
Article
PubMed
Google Scholar
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001, 119 (1 Suppl): 64S-94S.
Article
CAS
PubMed
Google Scholar
Erkens PM, Prins MH: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010, CD001100-9
Magee KD, Sevcik W, Moher D, Rowe BH: Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev. 2003, CD002132-1
Font MA, Krupinski J, Arboix A: Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat. 2011, 2011: 607852-
PubMed
PubMed Central
Google Scholar
Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004, 126 (3 Suppl): 188S-203S.
Article
CAS
PubMed
Google Scholar
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995, 332 (20): 1330-1335. 10.1056/NEJM199505183322003.
Article
CAS
PubMed
Google Scholar
Schulman S, Beyth RJ, Kearon C, Levine MN: Hemorrhagic complications of anticoagulant and thrombolytic treatment: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008, 133 (6 Suppl): 257S-298S.
Article
CAS
PubMed
Google Scholar
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease efficacy and safety of subcutaneous enoxaparin in Non-Q-wave coronary events study group. N Engl J Med. 1997, 337 (7): 447-452. 10.1056/NEJM199708143370702.
Article
CAS
PubMed
Google Scholar
The FRAX.I.S. Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999, 20 (21): 1553-1562. 10.1053/euhj.1999.1879.
Article
Google Scholar
Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997, 96 (1): 61-68. 10.1161/01.CIR.96.1.61.
Article
CAS
PubMed
Google Scholar
Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP: Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing. Thromb Res. 2009, 123 (6): 845-847. 10.1016/j.thromres.2008.09.001.
Article
CAS
PubMed
Google Scholar
Macie C, Forbes L, Foster GA, Douketis JD: Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004, 125 (5): 1616-1621. 10.1378/chest.125.5.1616.
Article
PubMed
Google Scholar
Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, Lopez-Sendon J, Hod H, Murphy SA, Braunwald E: The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007, 49 (23): 2249-2255. 10.1016/j.jacc.2006.12.049.
Article
CAS
PubMed
Google Scholar
Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED: Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005, 294 (24): 3108-3116. 10.1001/jama.294.24.3108.
Article
CAS
PubMed
Google Scholar
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, et al: Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31 (19): 2369-2429.
Article
PubMed
Google Scholar
Lin BW, Yoshida D, Quinn J, Strehlow M: A better way to estimate adult patients' weights. Am J Emerg Med. 2009, 27 (9): 1060-1064. 10.1016/j.ajem.2008.08.018.
Article
PubMed
Google Scholar
Anglemyer BL, Hernandez C, Brice JH, Zou B: The accuracy of visual estimation of body weight in the ED. Am J Emerg Med. 2004, 22 (7): 526-529. 10.1016/j.ajem.2004.09.002.
Article
PubMed
Google Scholar
Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D: Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004, 110 (4): 392-398. 10.1161/01.CIR.0000136830.65073.C7.
Article
CAS
PubMed
Google Scholar
Al-Sallami HS, Barras MA, Green B, Duffull SB: Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet. 2010, 49 (9): 567-571. 10.2165/11532960-000000000-00000.
Article
CAS
PubMed
Google Scholar
Singer JP, Huang MY, Hui C, Blanc PD, Boettger RF, Golden J, Watkins K, Hoopes C, Leard LE: Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients. J Heart Lung Transplant. 2010, 29 (9): 1009-1013. 10.1016/j.healun.2010.04.018.
Article
PubMed
PubMed Central
Google Scholar
Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L: Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005, 116 (1): 41-50. 10.1016/j.thromres.2004.10.004.
Article
CAS
PubMed
Google Scholar
Schmid P, Fischer AG, Wuillemin WA: Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009, 139 (31–32): 438-452.
CAS
PubMed
Google Scholar
Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996, 26 (Suppl 2): 24-38.
CAS
PubMed
Google Scholar
Jacobs DR, Kroenke C, Crow R, Deshpande M, Gu DF, Gatewood L, Blackburn H: PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation. 1999, 100 (6): 599-607. 10.1161/01.CIR.100.6.599.
Article
PubMed
Google Scholar
Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, et al: Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol. 2003, 41 (1): 8-14. 10.1016/S0735-1097(02)02664-5.
Article
CAS
PubMed
Google Scholar
Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009, 7 (10): 1629-1632. 10.1111/j.1538-7836.2009.03556.x.
Article
CAS
PubMed
Google Scholar